2928519-36-0
2928519-36-0
Chemical Structure
Biological Activity: Sunakiment (AZD-8630) is a humanized IgG1λ monoclonal antibody inhibitor targeting thymic stromal lymphopoietin (TSLP), which enables direct airway delivery via a dry powder inhaler formulation. Sunakiment binds to TSLP and blocks its pro-inflammatory signal transduction. It is applicable to research on refractory asthma, asthma, and moderate-to-severe asthma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sunakiment | Sunakiment (AZD-8630) is a humanized IgG1λ monoclonal antibody inhibitor targeting thymic stromal lymphopoietin (TSLP), which enables direct airway delivery via a dry powder inhaler formulation. Sunakiment binds to TSLP and blocks its pro-inflammatory signal transduction. It is applicable to research on refractory asthma, asthma, and moderate-to-severe asthma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Komori HK, et al. Potential of alarmin-targeted bispecific and combination therapies in airway disease. Frontiers in allergy. 2025;6:1700060. [Content Brief]
-
[2]. Doffman S, et al. Phase 1 Safety and Efficacy of AZD8630/AMG 104 Inhaled Anti‑TSLP in Healthy Volunteers and Patients With Asthma on Medium‑High Dose Inhaled Corticosteroid (ICS) and Long‑Acting Beta‑agonist (LABA) With Elevated Baseline Fractional Exhaled Nitric Oxide (FeNO) [abstract]. Am J Respir Crit Care Med. 2024;209(Suppl 1):A1386.
- [3]. Doffman SR, et al. AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial. The Journal of allergy and clinical immunology. 2026 Apr 20. [Content Brief]
